These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 20532703)

  • 1. Management of hypertriglyceridemia in the diabetic patient.
    Jialal I; Amess W; Kaur M
    Curr Diab Rep; 2010 Aug; 10(4):316-20. PubMed ID: 20532703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.
    Ito MK
    Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol.
    Toth PP; Zarotsky V; Sullivan JM; Laitinen D
    Curr Med Res Opin; 2009 Jun; 25(6):1355-63. PubMed ID: 19425901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lipid therapy in patients with diabetes].
    Saely CH; Drexel H
    Wien Med Wochenschr; 2010 Jan; 160(1-2):25-9. PubMed ID: 20229158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
    Handelsman Y; Shapiro MD
    Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Combination Cholesterol-Lowering Therapy and Triglyceride-Lowering Therapy on Medical Costs in Patients With Type 2 Diabetes Mellitus.
    Nichols GA; Reynolds K; Olufade T; Kimes TM; O'Keeffe-Rosetti M; Sapp DS; Anzalone D; Fortmann SP
    Am J Cardiol; 2017 Feb; 119(3):410-415. PubMed ID: 27890243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological management of high triglycerides and low high-density lipoprotein cholesterol.
    Szapary PO; Rader DJ
    Curr Opin Pharmacol; 2001 Apr; 1(2):113-20. PubMed ID: 11714084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertriglyceridemia: the importance of identifying patients at risk.
    Kushner PA; Cobble ME
    Postgrad Med; 2016 Nov; 128(8):848-858. PubMed ID: 27710158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triglyceride as a risk factor for coronary artery disease.
    Gotto AM
    Am J Cardiol; 1998 Nov; 82(9A):22Q-25Q. PubMed ID: 9819100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating hypertriglyceridemia.
    Holub BJ
    CMAJ; 2007 Sep; 177(6):604; author reply 604-5. PubMed ID: 17846446
    [No Abstract]   [Full Text] [Related]  

  • 13. Cumulative non-HDL-cholesterol burden in patients with hypertriglyceridemia receiving long-term fibrate therapy: Real life data from a lipid clinic cohort.
    Kayıkçıoğlu M; Shahbazova S; İbrahimov F; Can LH
    Turk Kardiyol Dern Ars; 2020 Jun; 48(4):359-367. PubMed ID: 32519982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demystifying triglycerides: a practical approach for the clinician.
    Dunbar RL; Rader DJ
    Cleve Clin J Med; 2005 Aug; 72(8):661-6, 670-2, 674-5 passim. PubMed ID: 16122052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertriglyceridemia and cardiovascular risk reduction.
    Jacobson TA; Miller M; Schaefer EJ
    Clin Ther; 2007 May; 29(5):763-777. PubMed ID: 17697898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men.
    Vega GL; Grundy SM
    Am J Cardiol; 1998 Feb; 81(4A):36B-42B. PubMed ID: 9526812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
    Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing diabetic dyslipidemia: beyond statin therapy.
    Neeli H; Gadi R; Rader DJ
    Curr Diab Rep; 2009 Feb; 9(1):11-7. PubMed ID: 19192419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.